ClinicalTrials.gg
CompletedNCT02805790MMPOWER-2Updated Jul 17, 2020Results posted

Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study

A Phase 2 interventional study of Elamipretide and Placebo in Primary Mitochondrial Disease, sponsored by Stealth BioTherapeutics Inc.. Completed at 4 sites in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2020-07-17.

Sponsored by Stealth BioTherapeutics Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Mitochondrial Myopathies with a site in United States — 6 open to participants now, 8 under way, none of them phase 3. Mitochondrial Myopathies · United States.

Enrollment
10th of 12
30 · median 50
Started
2016
with 1 other
Phase 2
5 of 19
none open now
Registered
6th of 19
by date
Lead sponsor
4 of 19
Stealth BioTherapeutics Inc.

Among the 19 studies in Mitochondrial Myopathies with a site in United States, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2016, is one of 5 in phase 2, and was the 6th registered.

Mitochondrial Myopathies

46 studies on the registry are indexed under Mitochondrial Myopathies; 14 are open to participants now.

Browse Mitochondrial Myopathies studies →

Open to participants now

6 of the 19 studies in Mitochondrial Myopathies with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Mitochondrial Myopathies studies recruiting now, 8 (62%) set no upper age limit and 4 (31%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Mitochondrial Myopathies with a site in United States, or all of them as a file.
02

Study summary

This randomized, double-blind, placebo-controlled, crossover study screened 32 subjects with primary mitochondrial myopathy (PMM) to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of subcutaneous elamipretide in this patient population.

Read the detailed description

This randomized, double-blind, placebo-controlled, crossover study screened 32 subjects with primary mitochondrial myopathy (PMM) who had completed participation in the SPIMM-201 study where they had received 5 days of intravenous (IV) elamipretide (0.01, 0.10, or 0.25 mg/kg/hour infused for 2 hours) or placebo (randomized 3:1). The primary objective was to evaluate the effect of single daily subcutaneous (SC) doses of elamipretide administered for 4 weeks on the 6-minute walking distance (6MWD).

Subjects were randomized (1:1) to one of two sequence groups: 4-weeks of treatment with 40 mg elamipretide administered once daily SC in Treatment Period 1 followed by 4-weeks of treatment with placebo administered once daily SC in Treatment Period 2 (separated by a 4-week washout period), or vice versa. Each sequence group went through 5 distinct periods: Screening, Treatment Period 1, Washout, Treatment Period 2, and Follow-Up. Safety, tolerability, pharmacokinetics (PK), and efficacy of subcutaneous elamipretide in this patient population were analyzed.

03

Conditions studied

  • Primary Mitochondrial Disease

Keywords

  • Primary Mitochondrial Disease
  • Mitochondrial Myopathy
  • Elamipretide
  • MTP-131
  • Bendavia™
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject completed participation in the SPIMM-201 study without a significant protocol deviation that would suggest the subject may not be able to complete all study requirements in the opinion of the Sponsor
  • Subject must reside in North America for the duration of the study
  • Subject has not received study drug in the SPIMM-201 study within 3 weeks prior to Screening
  • Women of must agree to use 1 of the methods of specified in the protocol from the date they sign the form (ICF) until two months after the last dose of study drug
  • Subject has been on stable (unchanged and constant) medications (including over-the counter treatments, vitamins, or supplements) for at least 1 month prior to the Baseline Visit

Exclusion criteria

Exclusion Criteria:

  • Subject has any prior or current medical condition that, in the judgment of the Investigator, would prevent the subject from safely participating in and/or completing all study requirements (i.e. unstable angina or recent myocardial infarction)
  • Subject has received any compound and/or has participated in another interventional clinical study within 30 days prior to the Baseline Visit or is concurrently enrolled in any non-interventional research of any type judged to be scientifically or medically incompatible with the study as deemed by the Investigator in consultation with the Sponsor
  • Subject experienced an adverse reaction to study drug in the SPIMM-201 study that contraindicates further treatment with elamipretide in the opinion of the Investigator and/or Sponsor
  • Female subjects who are pregnant, planning to become pregnant, or lactating
  • Subject has undergone an in-patient hospitalization within the 1 month prior to the Screening Visit or is likely to need in-patient hospitalization or a surgical procedure during the course of the study
  • Subject has a ≤30 mL/min as calculated by the Cockcroft Gault equation
  • Subject has a interval (QTc) elongation defined as a QTc >450 msec in male subjects and >480msec in female subjects. Note: At the initial (ECG), if QTc exceeds these parameters, the ECG may be repeated 2 more times, and the average of the 3 QTc values used to determine the subjects eligibility
  • Subject has uncontrolled hypertension in the judgment of the Investigator (e.g. elevated above >160 mmHg systolic or >100 mmHg diastolic despite appropriate treatment on two consecutive readings)
  • Subject has a history of or allergy to any of the contained in the study drug
  • Subject has a history of active alcoholism or drug addiction during the year before the Screening Visit
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Elamipretide, Then Placebo

    Participants first received 40 mg of elamipretide once daily subcutaneously for 4 weeks. After a washout period of 4 weeks, they then received placebo administered once daily subcutaneously for 4 weeks.

    Drug: Elamipretide · Drug: Placebo

  • Placebo comparator
    Placebo, Then Elamipretide

    Participants first received placebo once daily subcutaneously for 4 weeks. After a washout period of 4 weeks, they then received 40 mg of elamipretide once daily subcutaneously for 4 weeks.

    Drug: Elamipretide · Drug: Placebo

Interventions

  • 4 weeks of treatment with 40 mg elamipretide administered once daily subcutaneously

    Also known as: Bendavia, MTP-131

  • DrugPlacebo

    4 weeks of treatment with placebo administered once daily subcutaneously

06

What researchers measure

Primary outcomes

  1. Distance Walked on the 6-minute Walk Test (6MWT) by Visit

    Distance in meters walked on the 6-minute walk test (6MWT) at end of treatment, where end of treatment means end of week 4 for Period 1 and end of week 12 for Period 2.

    Time frame: End of Week 4 and End of Week 12

Secondary outcomes

  1. Wrist Accelerometer Counts by Day

    Wrist Accelerometer Counts by the last 7 days prior to the date of the end of treatment visit; End of treatment being end of Week 4 for Treatment Period 1 and end of Week 12 for Treatment Period 2. Subjects wore an activity monitor, or wrist accelerometer, on their wrist daily (from the Screening Visit to the End-of-Study/Early Discontinuation Visit). As a measure of physical activity and mobility, subjects wore an activity monitor, or wrist accelerometer, which measured mean vector magnitude of accelerations per daywith higher counts indicating a more active status. Raw acceleration data was converted into proprietary counts which was used to estimate physical activity. The data was transformed from 30 Hz data into 1 minute epoch data; this 1 minute epoch data were used for the analysis of as the vector magnitude of the wrist data.

    Time frame: Last 7 days prior to the date of end of treatment visit

  2. Average Hip Accelerator Counts by Day

    Average Hip Accelerator Counts by last 7 days predose, and prior to end of treatment; End of treatment being Week 4 for Treatment Period 1 and Week 12 for Treatment Period 2. As a measure of physical activity and mobility, subjects wore an activity monitor, or hip accelerometer, on their hip (or belt line) daily during waking hours (minimum of at least 7 consecutive days immediately prior to study drug administration in each Treatment Period \[Predose; at Visit 2 for Treatment Period 1 and at Visit 4 for Treatment Period 2\]), and at the end of each Treatment Period \[at Visit 3 for Treatment Period 1 and Visit 5 for Treatment Period 2\]), which measured average acceleration per day, with higher counts indicating a more active status. Raw acceleration data was converted into proprietary counts which was used to estimate physical activity. The data was transformed from 30 Hz data into 1 minute epoch data; this 1 minute epoch data was used for the analysis of mean vertical axis (Y) cou

    Time frame: Last 7 days prior to the date of end of treatment visit

  3. Neuro-QoL Fatigue Short Form Score: Total T-Scores (Question 1-8)

    Participants respond to the following statements of the Quality of Life in Neurological Disorders Fatigue Assessment (Neuro-QOL Fatigue Item Bank at end of treatment: I felt exhausted;I felt that I had no energy; I felt fatigued; I was too tired to do my household chores;I was too tired to leave the house;I was frustrated by being too tired to do the things I wanted to do; I felt tired; I had to limit my social activity because I was tired.Individual response options range from a score of 1 to 5, where 1=Never, 2=Rarely, 3=Sometimes, 4=Often, and 5=Always for end of treatment, where end of treatment period is end of week 4 for period 1, and end of week 12 for period 2. Raw scores are calculated as simple summed scores to an Item Response Theory Metric referred to as the T-score metric. Higher T-score means more fatigue, which means a worse outcome, with possible scores ranging from 29.5 to 74.1. Mean population T-score and standard deviation was reported.

    Time frame: End of Week 4 and End of Week 12

  4. Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) Total Fatigue Score by Week

    Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) Total Fatigue score at end of treatment (sum of Q1 to Q4; tiredness/muscle weakness) is scored as follows: 1=Not at all, 2=Mild, 3=Moderate, and 4=Severe. Total score range is 4-16; lower score means less fatigue and better outcome, higher score means more fatigue and worse outcome. Participants rate the following: Tiredness at rest, Tiredness during activities, Muscle weakness at rest, Muscle weakness during activities, at the end of each treatment period, where end of treatment period is the weekly average of the last 7 days of week 4 for period 1 and the last 7 days of week 12 for period 2.

    Time frame: Last 7 days of Week 4 and Last 7 days of Week 12

  5. Triple Timed Up and Go (3TUG) Test by Visit

    Participant performed 3TUG test after the 6MWT, and after at least 15 minutes rest prior to study drug administration in each Treatment Period (End of Week 4 for Period 1 and End of Week 12 for Period 2.) Participant was directed to stand up from chair, walk at normal pace to the line on the floor 3 meters away,turn, walk back to the chair at normal pace, sit down again; activity was timed, in seconds. Activity is repeated 3 times consecutively without rest and an average time is calculated.

    Time frame: End of Week 4 and End of Week 12

  6. Patient Global Assessment [PGA] Score by Visit, Continuous

    Patient-reported current health status at end of treatment, where end of treatment means End of Week 4 for Period 1 and End of Week 12 for Period 2. PGA Scale is as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Higher score means worse health status, means worse outcome.

    Time frame: End of Week 4 and End of Week 12

  7. Patient Global Assessment by Visit, Categorical

    Patient-reported current health status at end of treatment, where end of treatment means End of Week 4 for Period 1 and End of Week 12 for Period 2. PGA Scale is as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Higher score means worse health status, means worse outcome. Excellent means excellent health, means better outcome; poor means poor health, means worse outcome.

    Time frame: End of Week 4 and End of Week 12

  8. Physician Global Assessment (PhGA) By Visit, Continuous

    Physician Global Assessment (PhGA) Physician-reported overall health status at end of treatment, where end of treatment means End of Week 4 for Period 1 and End of Week 12 for Period 2.: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Higher scores equal worse outcome.

    Time frame: End of Week 4 and End of Week 12

  9. Physician Global Assessment (PhGA) By Visit, Categorical

    Physician Global Assessment (PhGA) Physician-reported overall health status at end of treatment, where end of treatment means End of Week 4 for Period 1 and End of Week 12 for Period 2.: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Higher scores equal worse outcome. Excellent means excellent health, means better outcome; poor means poor health, means worse outcome.

    Time frame: End of Week 4 and End of Week 12

07

Results

Posted Jul 7, 2020

Participant flow

First Intervention (4 Weeks)
Participant flow — First Intervention (4 Weeks)
MilestoneElamipretide, Then PlaceboPlacebo, Then Elamipretide
Started1416
Completed1416
Not completed00
Washout (4 Weeks)
Participant flow — Washout (4 Weeks)
MilestoneElamipretide, Then PlaceboPlacebo, Then Elamipretide
Started1416
Completed1416
Not completed00
Second Intervention (4 Weeks)
Participant flow — Second Intervention (4 Weeks)
MilestoneElamipretide, Then PlaceboPlacebo, Then Elamipretide
Started1416
Completed1415
Not completed01
Withdrew: Physician decision01

Outcome measures

PrimaryDistance Walked on the 6-minute Walk Test (6MWT) by Visit

Distance in meters walked on the 6-minute walk test (6MWT) at end of treatment, where end of treatment means end of week 4 for Period 1 and end of week 12 for Period 2.

Time frame:
End of Week 4 and End of Week 12
Reported as:
Mean · meters
Distance Walked on the 6-minute Walk Test (6MWT) by Visit
metersElamipretidePlacebo
Distance Walked on the 6-minute Walk Test (6MWT) by Visit394.1 ± 134.16378.2 ± 125.10
SecondaryWrist Accelerometer Counts by Day

Wrist Accelerometer Counts by the last 7 days prior to the date of the end of treatment visit; End of treatment being end of Week 4 for Treatment Period 1 and end of Week 12 for Treatment Period 2. Subjects wore an activity monitor, or wrist accelerometer, on their wrist daily (from the Screening Visit to the End-of-Study/Early Discontinuation Visit). As a measure of physical activity and mobility, subjects wore an activity monitor, or wrist accelerometer, which measured mean vector magnitude of accelerations per daywith higher counts indicating a more active status. Raw acceleration data was converted into proprietary counts which was used to estimate physical activity. The data was transformed from 30 Hz data into 1 minute epoch data; this 1 minute epoch data were used for the analysis of as the vector magnitude of the wrist data.

Time frame:
Last 7 days prior to the date of end of treatment visit
Reported as:
Mean · counts by day
Wrist Accelerometer Counts by Day
counts by dayElamipretidePlacebo
Wrist Accelerometer Counts by Day1329.4 ± 505.281286.3 ± 507.83
SecondaryAverage Hip Accelerator Counts by Day

Average Hip Accelerator Counts by last 7 days predose, and prior to end of treatment; End of treatment being Week 4 for Treatment Period 1 and Week 12 for Treatment Period 2. As a measure of physical activity and mobility, subjects wore an activity monitor, or hip accelerometer, on their hip (or belt line) daily during waking hours (minimum of at least 7 consecutive days immediately prior to study drug administration in each Treatment Period \[Predose; at Visit 2 for Treatment Period 1 and at Visit 4 for Treatment Period 2\]), and at the end of each Treatment Period \[at Visit 3 for Treatment Period 1 and Visit 5 for Treatment Period 2\]), which measured average acceleration per day, with higher counts indicating a more active status. Raw acceleration data was converted into proprietary counts which was used to estimate physical activity. The data was transformed from 30 Hz data into 1 minute epoch data; this 1 minute epoch data was used for the analysis of mean vertical axis (Y) cou

Time frame:
Last 7 days prior to the date of end of treatment visit
Reported as:
Mean · counts by day
Average Hip Accelerator Counts by Day
counts by dayElamipretidePlacebo
Predose384.2 ± 130.70380.6 ± 126.43
End of Treatment150.6 ± 162.13148.1 ± 115.04
SecondaryNeuro-QoL Fatigue Short Form Score: Total T-Scores (Question 1-8)

Participants respond to the following statements of the Quality of Life in Neurological Disorders Fatigue Assessment (Neuro-QOL Fatigue Item Bank at end of treatment: I felt exhausted;I felt that I had no energy; I felt fatigued; I was too tired to do my household chores;I was too tired to leave the house;I was frustrated by being too tired to do the things I wanted to do; I felt tired; I had to limit my social activity because I was tired.Individual response options range from a score of 1 to 5, where 1=Never, 2=Rarely, 3=Sometimes, 4=Often, and 5=Always for end of treatment, where end of treatment period is end of week 4 for period 1, and end of week 12 for period 2. Raw scores are calculated as simple summed scores to an Item Response Theory Metric referred to as the T-score metric. Higher T-score means more fatigue, which means a worse outcome, with possible scores ranging from 29.5 to 74.1. Mean population T-score and standard deviation was reported.

Time frame:
End of Week 4 and End of Week 12
Reported as:
Mean · T-score
Neuro-QoL Fatigue Short Form Score: Total T-Scores (Question 1-8)
T-scoreElamipretidePlacebo
Neuro-QoL Fatigue Short Form Score: Total T-Scores (Question 1-8)50.9 ± 7.6954.7 ± 10.35
SecondaryPrimary Mitochondrial Myopathy Symptom Assessment (PMMSA) Total Fatigue Score by Week

Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) Total Fatigue score at end of treatment (sum of Q1 to Q4; tiredness/muscle weakness) is scored as follows: 1=Not at all, 2=Mild, 3=Moderate, and 4=Severe. Total score range is 4-16; lower score means less fatigue and better outcome, higher score means more fatigue and worse outcome. Participants rate the following: Tiredness at rest, Tiredness during activities, Muscle weakness at rest, Muscle weakness during activities, at the end of each treatment period, where end of treatment period is the weekly average of the last 7 days of week 4 for period 1 and the last 7 days of week 12 for period 2.

Time frame:
Last 7 days of Week 4 and Last 7 days of Week 12
Reported as:
Mean · score on a scale
Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) Total Fatigue Score by Week
score on a scaleElamipretidePlacebo
Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) Total Fatigue Score by Week9.1 ± 2.3510.7 ± 2.88
SecondaryTriple Timed Up and Go (3TUG) Test by Visit

Participant performed 3TUG test after the 6MWT, and after at least 15 minutes rest prior to study drug administration in each Treatment Period (End of Week 4 for Period 1 and End of Week 12 for Period 2.) Participant was directed to stand up from chair, walk at normal pace to the line on the floor 3 meters away,turn, walk back to the chair at normal pace, sit down again; activity was timed, in seconds. Activity is repeated 3 times consecutively without rest and an average time is calculated.

Time frame:
End of Week 4 and End of Week 12
Reported as:
Mean · seconds
Triple Timed Up and Go (3TUG) Test by Visit
secondsElamipretidePlacebo
Triple Timed Up and Go (3TUG) Test by Visit35.3 ± 16.6635.2 ± 15.79
SecondaryPatient Global Assessment [PGA] Score by Visit, Continuous

Patient-reported current health status at end of treatment, where end of treatment means End of Week 4 for Period 1 and End of Week 12 for Period 2. PGA Scale is as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Higher score means worse health status, means worse outcome.

Time frame:
End of Week 4 and End of Week 12
Reported as:
Mean · score on a scale
Patient Global Assessment [PGA] Score by Visit, Continuous
score on a scaleElamipretidePlacebo
Patient Global Assessment [PGA] Score by Visit, Continuous3.4 ± 0.913.7 ± 1.01
SecondaryPatient Global Assessment by Visit, Categorical

Patient-reported current health status at end of treatment, where end of treatment means End of Week 4 for Period 1 and End of Week 12 for Period 2. PGA Scale is as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Higher score means worse health status, means worse outcome. Excellent means excellent health, means better outcome; poor means poor health, means worse outcome.

Time frame:
End of Week 4 and End of Week 12
Reported as:
Count of participants · Participants
Patient Global Assessment by Visit, Categorical
ParticipantsElamipretidePlacebo
Excellent11
Very Good22
Good128
Fair1112
Poor37
SecondaryPhysician Global Assessment (PhGA) By Visit, Continuous

Physician Global Assessment (PhGA) Physician-reported overall health status at end of treatment, where end of treatment means End of Week 4 for Period 1 and End of Week 12 for Period 2.: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Higher scores equal worse outcome.

Time frame:
End of Week 4 and End of Week 12
Reported as:
Mean · score on a scale
Physician Global Assessment (PhGA) By Visit, Continuous
score on a scaleElamipretidePlacebo
Physician Global Assessment (PhGA) By Visit, Continuous3.1 ± 0.803.3 ± 0.84
SecondaryPhysician Global Assessment (PhGA) By Visit, Categorical

Physician Global Assessment (PhGA) Physician-reported overall health status at end of treatment, where end of treatment means End of Week 4 for Period 1 and End of Week 12 for Period 2.: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Higher scores equal worse outcome. Excellent means excellent health, means better outcome; poor means poor health, means worse outcome.

Time frame:
End of Week 4 and End of Week 12
Reported as:
Count of participants · Participants
Physician Global Assessment (PhGA) By Visit, Categorical
ParticipantsElamipretidePlacebo
Excellent00
Very Good65
Good1713
Fair410
Poor22

Adverse events

Collected over Participants were followed for a total of 14 weeks; they had a Treatment Period for 4 weeks, then had a Washout Period of 4 weeks, then another Treatment Period of 4 weeks, then a Follow Up Period of 2 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Elamipretide0/30 (0%)0/30 (0%)30/30 (100%)
Placebo0/30 (0%)0/30 (0%)15/30 (50%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventElamipretidePlacebo
Injection site erythemaGeneral disorders17/301/30
Injection site pruritusGeneral disorders14/300/30
Injection site painGeneral disorders6/301/30
Injection site urticariaGeneral disorders6/300/30
Injection site irritationGeneral disorders3/301/30
DizzinessNervous system disorders3/301/30
FallInjury, poisoning and procedural complications1/303/30
Injection site bruisingGeneral disorders2/302/30
Urinary Tract InfectionInfections and infestations2/300/30
Viral Upper Respiratory Tract InfectionInfections and infestations2/300/30

Baseline characteristics

Age, Continuous
Age, Continuous(years)Elamipretide, Then PlaceboPlacebo, Then ElamipretideTotal
Mean41.5 ± 16.6748.6 ± 9.6845.3 ± 13.63
Sex: Female, Male
Sex: Female, Male(Participants)Elamipretide, Then PlaceboPlacebo, Then ElamipretideTotal
Female101525
Male415
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Elamipretide, Then PlaceboPlacebo, Then ElamipretideTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White131629
More than one race101
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Elamipretide, Then PlaceboPlacebo, Then ElamipretideTotal
United States141630
Body Mass Index
Body Mass Index(kg/m^2)Elamipretide, Then PlaceboPlacebo, Then ElamipretideTotal
Mean22.8 ± 5.1925.3 ± 5.4624.1 ± 5.39
08

Study locations

4 sites
  • University of California
    San Diego, California 92093, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Akron Children's Hospital
    Akron, Ohio 44308, United States
  • Children's Hospital of Pittsburg of UPMC
    Pittsburgh, Pennsylvania 15224, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2016 to primary completion in Mar 2017, 6 months.

Results were first posted in Jul 2020, 3 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2016
First posted
Jun 20, 2016
StartActual
Aug 22, 2016
Primary completionActual
Mar 10, 2017
CompletionActual
Mar 23, 2017
Results first posted
Jul 7, 2020
Last update
Jul 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02805790
Responsible party
Sponsor
First posted
Jun 20, 2016
Start date
Aug 22, 2016
Primary completion
Mar 10, 2017
Completion
Mar 23, 2017
Results posted
Jul 7, 2020
Last update
Jul 17, 2020

Study contacts

Jim Carr
study director · Stealth BioTherapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elamipretide

Start the discussion